<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582010</url>
  </required_header>
  <id_info>
    <org_study_id>F070112003</org_study_id>
    <nct_id>NCT00582010</nct_id>
  </id_info>
  <brief_title>Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation</brief_title>
  <official_title>Effects of Inhaled Nitric Oxide on Ischemia-Reperfusion Injury in Human Liver During Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This blinded, placebo-controlled study will administer inhaled nitric oxide to patients
      undergoing liver transplantation. The purpose of the study is to test if inhaled nitric oxide
      prevents liver injury associated with the restoration of blood flow. The premise of the
      current study is provided by previous studies which document a protective effect of inhaled
      nitric oxide in this clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specifically, presenting ischemia-reperfusion injury to transplanted livers remains a
      therapeutic goal in improving liver function and potentially expanding the number of
      transplantable livers. This study aims to assess the efficacy of inhaled nitric oxide to
      limit ischemia-reperfusion injury in transplanted livers and by doing so improve liver
      function post transplantation and decrease patient hospital length of stays.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels)</measure>
    <time_frame>baseline and 96 hours after baseline</time_frame>
    <description>The faster the percent decrease of AST reflect the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. The rate was calculated by measuring AST levels at baseline and at 96 hours post baseline. (AST levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of AST relative to baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in ALT Levels)</measure>
    <time_frame>baseline and 96 hours after baseline</time_frame>
    <description>The faster the percent decrease ALT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. . (ALT levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of ALT relative to baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Alkaline Phosphatase Levels)</measure>
    <time_frame>baseline and 96 hours after baseline</time_frame>
    <description>The faster the percent increase of alkaline phosphatase reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an increase; a negative percentage reflects a decrease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Prothrombin Times (PT))</measure>
    <time_frame>baseline and 96 hours after baseline</time_frame>
    <description>The faster the percent increase of PT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Bilirubin Levels)</measure>
    <time_frame>baseline and 96 hours after baseline</time_frame>
    <description>A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rate of Liver Function Recovery Post-transplantation (Decrease in Hepatobiliary Complications)</measure>
    <time_frame>baseline to 9 months after transplantation</time_frame>
    <description>Number of complications due to hepatobiliary events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Complications Related to Liver Function Recovery Post-transplantation (Total Complications) at 9 Months Post Surgery</measure>
    <time_frame>baseline to 9 months post surgery</time_frame>
    <description>Number of any complication reported by subjects at 9 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of iNO on Hosptial Length of Stay</measure>
    <time_frame>from surgery through discharge from hospital</time_frame>
    <description>number of days subject in hospital after surgery until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of iNO on SICU Stay</measure>
    <time_frame>baseline to discharge for SICU</time_frame>
    <description>Number of minutes after surgery subject remained in SICU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Reperfusion Injury</condition>
  <condition>Liver Injury</condition>
  <arm_group>
    <arm_group_label>1. Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iNO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (nitrogen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled nitric oxide</intervention_name>
    <description>inhaled 80ppm for duration of surgery.</description>
    <arm_group_label>1. Experimental</arm_group_label>
    <other_name>iNO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitrogen gas</intervention_name>
    <description>inhaled</description>
    <arm_group_label>2. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 19 yr of age scheduled to undergo liver transplantation.

        Exclusion Criteria:

          -  Patients &lt; 19 yr of age

          -  Patients undergoing re-transplantation or dual organ transplantation

          -  Patients with underlying pulmonary complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh P Patel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith A Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Devin E Eckhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John S Bynon, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blair Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clark Cross, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc Frenette, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John D Lang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon JS, Eckhoff DE, Patel RP. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest. 2007 Sep;117(9):2583-91.</citation>
    <PMID>17717604</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <results_first_submitted>September 30, 2013</results_first_submitted>
  <results_first_submitted_qc>November 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2014</results_first_posted>
  <disposition_first_submitted>October 12, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 15, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 24, 2010</disposition_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Rakesh Patel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ischemia-reperfusion</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>inflammation</keyword>
  <keyword>cell-death</keyword>
  <keyword>Liver-function post transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1. Experimental</title>
          <description>iNO administration
inhaled nitric oxide : inhaled 80ppm for duration of surgery.</description>
        </group>
        <group group_id="P2">
          <title>2. Placebo</title>
          <description>Placebo (nitrogen)
nitrogen gas : inhaled</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>80 ppm was administered by inhalation for the duration of surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Nitrogen Gas)</title>
          <description>80 ppm was administered by inhalation for the duration of surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="4" lower_limit="30" upper_limit="72"/>
                    <measurement group_id="B2" value="61" lower_limit="24" upper_limit="70"/>
                    <measurement group_id="B3" value="60" lower_limit="24" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels)</title>
        <description>The faster the percent decrease of AST reflect the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. The rate was calculated by measuring AST levels at baseline and at 96 hours post baseline. (AST levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of AST relative to baseline).</description>
        <time_frame>baseline and 96 hours after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels)</title>
          <description>The faster the percent decrease of AST reflect the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. The rate was calculated by measuring AST levels at baseline and at 96 hours post baseline. (AST levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of AST relative to baseline).</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="14.6"/>
                    <measurement group_id="O2" value="86.4" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of iNO on Hosptial Length of Stay</title>
        <description>number of days subject in hospital after surgery until discharge</description>
        <time_frame>from surgery through discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Effect of iNO on Hosptial Length of Stay</title>
          <description>number of days subject in hospital after surgery until discharge</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="7.5" upper_limit="15.5"/>
                    <measurement group_id="O2" value="9.0" lower_limit="7" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in ALT Levels)</title>
        <description>The faster the percent decrease ALT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. . (ALT levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of ALT relative to baseline).</description>
        <time_frame>baseline and 96 hours after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in ALT Levels)</title>
          <description>The faster the percent decrease ALT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. . (ALT levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of ALT relative to baseline).</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="26.8"/>
                    <measurement group_id="O2" value="62.4" spread="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Alkaline Phosphatase Levels)</title>
        <description>The faster the percent increase of alkaline phosphatase reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an increase; a negative percentage reflects a decrease.</description>
        <time_frame>baseline and 96 hours after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Alkaline Phosphatase Levels)</title>
          <description>The faster the percent increase of alkaline phosphatase reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an increase; a negative percentage reflects a decrease.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.7" spread="672.4"/>
                    <measurement group_id="O2" value="55" spread="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Prothrombin Times (PT))</title>
        <description>The faster the percent increase of PT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
        <time_frame>baseline and 96 hours after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Prothrombin Times (PT))</title>
          <description>The faster the percent increase of PT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="9.9"/>
                    <measurement group_id="O2" value="25.5" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Bilirubin Levels)</title>
        <description>A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
        <time_frame>baseline and 96 hours after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Bilirubin Levels)</title>
          <description>A positive percent reflects an decrease; a negative percentage reflects a increase.</description>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="57"/>
                    <measurement group_id="O2" value="0.4" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of iNO on SICU Stay</title>
        <description>Number of minutes after surgery subject remained in SICU</description>
        <time_frame>baseline to discharge for SICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Effect of iNO on SICU Stay</title>
          <description>Number of minutes after surgery subject remained in SICU</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2533" lower_limit="1983" upper_limit="3075"/>
                    <measurement group_id="O2" value="2518" lower_limit="1703" upper_limit="3802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rate of Liver Function Recovery Post-transplantation (Decrease in Hepatobiliary Complications)</title>
        <description>Number of complications due to hepatobiliary events.</description>
        <time_frame>baseline to 9 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Rate of Liver Function Recovery Post-transplantation (Decrease in Hepatobiliary Complications)</title>
          <description>Number of complications due to hepatobiliary events.</description>
          <units>Complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Complications Related to Liver Function Recovery Post-transplantation (Total Complications) at 9 Months Post Surgery</title>
        <description>Number of any complication reported by subjects at 9 months after surgery</description>
        <time_frame>baseline to 9 months post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Complications Related to Liver Function Recovery Post-transplantation (Total Complications) at 9 Months Post Surgery</title>
          <description>Number of any complication reported by subjects at 9 months after surgery</description>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1. Experimental</title>
          <description>iNO administration
inhaled nitric oxide : inhaled 80ppm for duration of surgery.</description>
        </group>
        <group group_id="E2">
          <title>2. Placebo</title>
          <description>Placebo (nitrogen)
nitrogen gas : inhaled</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rakesh Patel</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-3411</phone>
      <email>rakeshp@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

